Satsuma Pharmaceuticals, Inc.
STSA · NASDAQ
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $7,459 | $8,698 | $11,342 | $12,496 |
| G&A Expenses | $3,309 | $3,165 | $4,067 | $3,904 |
| SG&A Expenses | $3,309 | $3,165 | $4,067 | $3,904 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $10,768 | $11,863 | $15,409 | $16,400 |
| Operating Income | -$10,768 | -$23,592 | -$15,409 | -$16,400 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $474 | $462 | $269 | $132 |
| Pre-Tax Income | -$10,294 | -$23,130 | -$15,140 | -$16,268 |
| Tax Expense | -$474 | -$623 | -$269 | -$132 |
| Net Income | -$9,820 | -$22,507 | -$14,871 | -$16,136 |
| % Margin | – | – | – | – |
| EPS | -0.3 | -0.68 | -0.47 | -0.51 |
| % Growth | 55.9% | -44.7% | 7.8% | – |
| EPS Diluted | -0.3 | -0.68 | -0.47 | -0.51 |
| Weighted Avg Shares Out | 33,152 | 33,131 | 31,855 | 31,553 |
| Weighted Avg Shares Out Dil | 33,152 | 33,131 | 31,855 | 31,553 |
| Supplemental Information | – | – | – | – |
| Interest Income | $474 | $462 | $269 | $134 |
| Interest Expense | -$474 | $0 | $269 | $2 |
| Depreciation & Amortization | $511 | $12,191 | $458 | $277 |
| EBITDA | -$10,257 | -$11,401 | -$14,951 | -$16,123 |
| % Margin | – | – | – | – |